NEW YORK (GenomeWeb) – As part of their effort to develop an RNAi-based therapy for hepatitis B infection, researchers from the University of the Witwatersrand in South Africa have developed self-inactivated lentiviral vectors that generate liver-specific microRNA-based RNAi activators that target different portions of the virus's genome.

In addition to their potential for the treatment of HBV, the vectors may also be applicable to other hepatic viral infections and the ex vivo modification of hepatocytes or induced hepatocyte progenitors.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.

May
08
Sponsored by
Dovetail Genomics

This webinar will discuss a proximity ligation-based method for studying structural variation in formalin-fixed paraffin-embedded (FFPE) tissue.